search icon

    Market Snapshot

    • S&P Futures

      3,809.5

    • Dow Futures

      30,868

    • Nasdaq Futures

      11,633.25

    blog search icon

    Galapagos NV (GLPG) Stock Trending Lower Despite Successful Topline Results from GLPG3667 and GLPG 3970 Studies

    By ST Staff

    Jul 15,2021

    4:25 AM UTC

    Galapagos NV (GLPG) stock prices were down a marginal 1.79% as of the market closing on July 14th, 2021, bringing the price per share down to USD$65.80. Subsequent premarket fluctuations have seen the stock fall by 11.14%, bringing it down to USD$58.47.

    GLPG3667

    July 14th, 2021 saw the company announce positive topline results from the evaluation of GLPG3667, a proprietary TYK2 compound. The randomized, placebo-controlled, double-blind Phase 1b study had a total of 31 patients enrolled, each with a diagnosis ranging from moderate to severe plaque psoriasis. Patients were randomized in a 1:1:1 ratio and were administered a daily oral dose of GLPG3667 or a placebo over the course of four weeks. The main objectives of the study were to evaluate the safety and tolerability of the treatment, as well as signs indicating clinical activity.

    Success of the Study

    The treatment was found to be well tolerated during the course of the trial, barring one patient in the low dose group having interrupted the study for one day on account of the exacerbation of psoriasis. Any treatment related adverse events were mild in nature and transient, with no deaths or serious adverse events being reported. By Week 4, 40% of patients in the high dose group had a PASI 50 response, which is indicative of a minimum 50% improvement in PASI from baseline.

    GLPG3970

    Concurrently, the company announced the success of topline results from three patient studies for GLPG3970. The study evaluated the proprietary salt inducible kinase 2/3 inhibitor. The studies were randomized, placebo-controlled, double blind, with a Phase 1b study in patients with moderate to severe psoriasis. Two Phase 2a studies were also conducted in patients with moderate to severely active UC and RA.

    Continued Success

    With the treatment being administered orally once-daily for a period of 6 weeks, the main objectives were to evaluate the safety and tolerability of GLPG3970, as well as early signs of biologic and clinical effect. The treatment was generally safe and well tolerated across all three studies. No deaths or serious adverse events were reported, while the majority of treatment emergent adverse events were mild to moderate in nature.

    Future Outlook for GLPG

    Armed with the success of its various studies, GLPG is poised to capitalize on the opportunities presented to it as it further develops its flagship treatments. The company is keen to push for the accelerated development and eventual commercialization of its pipeline of products. Investors are hopeful that the proliferation of the treatment will result in sustained and significant increases in shareholder value.

    More From Stocks telegraph